First-line drug treatment for tuberculosis (TB) is frequently associated with liver toxicity. The goal of this study was to examine the association between UDP-glucuronosyl- transferase 1A1 (UGT1A1) genetic variations and anti-tuberculosis drug-induced hepatotoxicity (ATDH). A total of 98 patients, including 17 patients with ATDH, were enrolled; compound UGT1A1*27 and UGT1A1*28 were associated with an increased risk for developing ATDH after adjusting for age (OR 13.859; 95%CI 1.085-177.056). These findings require confirmation. However, screening for genetic variations prior to TB treatment may reduce the incidence of ATDH and improve treatment adherence.

Original languageEnglish
Pages (from-to)376-378
Number of pages3
JournalInternational Journal of Tuberculosis and Lung Disease
Issue number3
Publication statusPublished - Mar 1 2012


  • ATDH
  • Anti-tuberculosis drug-induced hepatotoxicity
  • NAT2
  • UGT1A1

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'UGT1A1 polymorphisms associated with risk of induced liver disorders by anti-tuberculosis medications'. Together they form a unique fingerprint.

Cite this